Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Surgery Partners Inc (NASDAQ: SGRY) closed at $22.86 down -4.11% from its previous closing price of $23.84. In other words, the price has decreased by -$4.11 from its previous closing price. On the day, 1.66 million shares were traded. SGRY stock price reached its highest trading level at $24.1 during the session, while it also had its lowest trading level at $22.81.
Ratios:
For a deeper understanding of Surgery Partners Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.72. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 2.22 whereas as Long-Term Debt/Eq ratio is at 2.13.
On December 16, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $30.
On October 14, 2024, UBS started tracking the stock assigning a Buy rating and target price of $38.UBS initiated its Buy rating on October 14, 2024, with a $38 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 21 ’25 when Wayne DeVeydt bought 100,000 shares for $22.99 per share.
DeLuca Teresa sold 20,018 shares of SGRY for $455,209 on Aug 11 ’25. The Director now owns 45,173 shares after completing the transaction at $22.74 per share. On Aug 11 ’25, another insider, Maryland Patricia Anne, who serves as the Director of the company, sold 20,018 shares for $22.74 each. As a result, the insider received 455,209 and left with 4,565 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 2930857728 and an Enterprise Value of 8382894080. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.91 while its Price-to-Book (P/B) ratio in mrq is 1.68. Its current Enterprise Value per Revenue stands at 2.59 whereas that against EBITDA is 12.999.
Stock Price History:
The Beta on a monthly basis for SGRY is 1.76, which has changed by -0.32146037 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, SGRY has reached a high of $33.97, while it has fallen to a 52-week low of $18.87. The 50-Day Moving Average of the stock is 2.97%, while the 200-Day Moving Average is calculated to be -0.49%.
Shares Statistics:
For the past three months, SGRY has traded an average of 1.71M shares per day and 1601630 over the past ten days. A total of 128.21M shares are outstanding, with a floating share count of 75.97M. Insiders hold about 40.74% of the company’s shares, while institutions hold 74.86% stake in the company. Shares short for SGRY as of 1753920000 were 12831465 with a Short Ratio of 7.51, compared to 1751241600 on 11426092. Therefore, it implies a Short% of Shares Outstanding of 12831465 and a Short% of Float of 21.219999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating of Surgery Partners Inc (SGRY) is currently shaped by the ongoing analysis conducted by 12.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.47, with high estimates of $0.61 and low estimates of $0.32.
Analysts are recommending an EPS of between $1.06 and $0.57 for the fiscal current year, implying an average EPS of $0.85. EPS for the following year is $1.02, with 12.0 analysts recommending between $1.65 and $0.69.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $824.04M this quarter.It ranges from a high estimate of $839.4M to a low estimate of $803.8M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $770.4MFor the next quarter, 12 analysts are estimating revenue of $930.64M. There is a high estimate of $951.2M for the next quarter, whereas the lowest estimate is $904.35M.
A total of 12 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.39B, while the lowest revenue estimate was $3.32B, resulting in an average revenue estimate of $3.36B. In the same quarter a year ago, actual revenue was $3.11BBased on 12 analysts’ estimates, the company’s revenue will be $3.69B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.62B.
